Condition: Prostate Cancer · Metastatic Castration-resistant Prostate Cancer · Metastatic Castration-resistant Prostate Carcinoma · Sponsor: Brigham and Women's Hospital
The purpose of this research study is to see how well an imaging test, called 18FDCFPyL prostate specific membrane antigen (PSMA) positron emission tomography (PET), can show the extent of prostate cancer when comparing to 68Ga-PSMA-11 PET/CT (another type of diagnostic scan for prostate cancer).
This description comes directly from the study's public registry record.
Heather Jacene, MD · 617-632-3767 · hjacene@partners.org
Always discuss trial participation with your own doctor first.
| Dana Farber Cancer Institute | Boston, Massachusetts, United States | Recruiting |
| Brigham and Womens Hospital | Boston, Massachusetts, United States | Recruiting |
Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.
We email about this public record only. Unsubscribe anytime with one click. Never medical advice.
This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.
Source record: clinicaltrials.gov/study/NCT06099093